Linsitinib
Tier C — Watch / tradeLinsitinib
Targets：IGF1R, INSR
Indications (approved)：甲状腺疾病, 甲状腺相关性眼病, 慢性淋巴细胞性甲状腺炎, 突眼症, Multiple myeloma, 唇肿瘤, 基底鳞状细胞癌, 口腔癌
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| LINSI-001 | 936901-73-4 | 3-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutan-1-one |
| LINSI-002 | 936901-74-5 | (1s,3s)-3-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol |
| LINSI-003 | 936901-75-6 | (1s,3s)-3-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol |
| LINSI-004 | 867164-54-3 | 2-phenyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline |
| Linsitinib | 867160-71-2 | (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol |
| Code | CAS No. | Intermediate |
|---|---|---|
| LINSI-005 | 612-60-2 | 7-methylquinoline |
| LINSI-006 | 591-51-5 | phenyllithium |
| LINSI-007 | 27356-39-4 | 7-methyl-2-phenylquinoline |
| LINSI-008 | 867162-43-4 | 2-phenylquinoline-7-carbaldehyde |
| LINSI-009 | 14508-49-7 | 2-chloropyrazine |
| LINSI-010 | 867162-41-2 | (3-chloropyrazin-2-yl)(2-phenylquinolin-7-yl)methanol |
| LINSI-011 | 85-41-6 | isoindoline-1,3-dione |
| LINSI-012 | 867162-39-8 | 2-((3-chloropyrazin-2-yl)(2-phenylquinolin-7-yl)methyl)isoindoline-1,3-dione |
| LINSI-013 | 867162-37-6 | (3-chloropyrazin-2-yl)(2-phenylquinolin-7-yl)methanamine |
| LINSI-014 | 15760-36-8 | 3-methylenecyclobutane-1-carboxylic acid |
| LINSI-015 | 867163-52-8 | N-((3-chloropyrazin-2-yl)(2-phenylquinolin-7-yl)methyl)-3-methylenecyclobutane-1-carboxamide |
| LINSI-016 | 867163-50-6 | 7-(8-chloro-3-(3-methylenecyclobutyl)imidazo[1,5-a]pyrazin-1-yl)-2-phenylquinoline |
| LINSI-017 | 867163-54-0 | 3-(8-chloro-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-(hydroxymethyl)cyclobutan-1-ol |
| LINSI-018 | 867165-62-6 | 3-(8-chloro-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)cyclobutan-1-one |
| LINSI-019 | 867163-02-8 | (1s,3s)-3-(8-chloro-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol |
Frequently asked questions
What are the approved indications of Linsitinib?
Approved indications include: 甲状腺疾病, 甲状腺相关性眼病, 慢性淋巴细胞性甲状腺炎, 突眼症, Multiple myeloma, 唇肿瘤, 基底鳞状细胞癌, 口腔癌.
When does the Linsitinib patent expire?
No public expiry year is available for Linsitinib yet; this page updates once verified.
How many synthesis routes are recorded for Linsitinib?
2 synthesis routes are recorded; the shortest is 3 steps with 15.6 kg (Linsitinib) total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Linsitinib intermediates?
All intermediates in Linsitinib routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Linsitinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21